Journal ArticleDOI
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina A. Singh,Terri L. Parker,Alex R. Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar +19 more
Reads0
Chats0
TLDR
In this randomized phase 3 trial, KRd did not improve PFS compared with VRd in NDMM and VRd remains the standard triplet induction regimen in standard and intermediate risk NDMM, and a suitable backbone for 4 drug combinations.Abstract:
LBA3Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in...read more
Citations
More filters
Journal ArticleDOI
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
M.A. Dimopoulos,P. Moreau,E. Terpos,M.V. Mateos,Sonja Zweegman,Gordon Cook,Michel Delforge,Roman Hájek,Fredrik Schjesvold,Michele Cavo,H. Goldschmidt,Thierry Facon,H. Einsele,Mario Boccadoro,Jesús F. San-Miguel,Pieter Sonneveld,U. Mey +16 more
Journal ArticleDOI
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jagoda Jasielec,Tadeusz Kubicki,Tadeusz Kubicki,Noopur Raje,Ravi Vij,Donna E. Reece,Jesus G. Berdeja,Benjamin A. Derman,Cara A. Rosenbaum,Cara A. Rosenbaum,Paul G. Richardson,Sandeep Gurbuxani,Sarah Major,Brittany Wolfe,Andrew T. Stefka,Leonor A Stephens,Kathryn M. Tinari,Tyler Hycner,Alexandra E Rojek,Dominik Dytfeld,Dominik Dytfeld,Kent A. Griffith,Todd M. Zimmerman,Andrzej Jakubowiak +23 more
TL;DR: This phase 2 multicenter study evaluated incorporation of autologous stem cell transplant (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma and met the primary endpoint, with an sCR rate of 60% after 8 cycles.
Journal ArticleDOI
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Thierry Facon,Christopher P. Venner,Nizar J. Bahlis,Fritz Offner,Darrell White,Lionel Karlin,Lotfi Benboubker,Sophie Rigaudeau,Philippe Rodon,Eric Voog,Sung-Soo Yoon,Kenshi Suzuki,Hirohiko Shibayama,Xiaoquan Zhang,Philip Twumasi-Ankrah,Godwin Yung,Robert M. Rifkin,Philippe Moreau,Sagar Lonial,Shaji Kumar,Paul G. Richardson,S. Vincent Rajkumar +21 more
TL;DR: The TOURMALINE-MM2 trial as discussed by the authors showed that the oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities.
Journal ArticleDOI
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020.
Arthur Bobin,Evelyne Liuu,Niels Moya,Cécile Gruchet,Florence Sabirou,Anthony Levy,Helene Gardeney,Laly Nsiala,Laura Cailly,Stéphanie Guidez,Cécile Tomowiak,Thomas Systchenko,Vincent Javaugue,Geraldine Durand,Xavier Leleu,Mathieu Puyade +15 more
TL;DR: The most recent advances in MM therapeutics, which have undergone major transformations over the past decade, are enumerated and comment on.
Journal ArticleDOI
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.
Adrián Mosquera Orgueira,Marta Sonia González Pérez,José Ángel Díaz Arias,Beatriz Antelo Rodríguez,Natalia Alonso Vence,Ángeles Bendaña López,Aitor Abuin Blanco,Laura Bao Pérez,Andrés Peleteiro Raíndo,Miguel Cid López,Manuel Mateo Pérez Encinas,José Luis Bello López,Maria Victoria Mateos Manteca +12 more
TL;DR: In this paper, a 50-variable random forests model (IAC-50) was used to predict overall survival with high concordance between both training and validation sets (c-indexes, 0.818 and 0.780), which included the following covariates: patient age, ISS stage, serum B2-microglobulin, first-line treatment, and expression of 46 genes.
Related Papers (5)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Michel Attal,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Christopher Chiu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Ming Qi,Saad Z. Usmani,Maia Trial Investigators +30 more
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Karim Belhadj,Lotfi Benboubker,Marie C. Béné,Annemiek Broijl,Hélène Caillon,Denis Caillot,Jill Corre,Michel Delforge,Thomas Dejoie,Chantal Doyen,Thierry Facon,Cécile Sonntag,Jean Fontan,Laurent Garderet,Kon-Siong Jie,Lionel Karlin,Frédérique Kuhnowski,Jérôme J. Lambert,Xavier Leleu,Pascal Lenain,Margaret Macro,Claire Mathiot,Frédérique Orsini-Piocelle,Aurore Perrot,Anne-Marie Stoppa,Niels W.C.J. van de Donk,Soraya Wuilleme,Sonja Zweegman,Brigitte Kolb,Cyrille Touzeau,Murielle Roussel,Mourad Tiab,Jean-Pierre Marolleau,Nathalie Meuleman,Marie-Christiane Vekemans,Matthijs Westerman,Saskia K. Klein,Mark-David Levin,Jean Paul Fermand,Martine Escoffre-Barbe,Jean-Richard Eveillard,Reda Garidi,Tahamtan Ahmadi,Sen Zhuang,Christopher Chiu,Lixia Pei,Carla de Boer,Elena Smith,William Deraedt,Tobias Kampfenkel,Jordan M. Schecter,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld +57 more
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Maria-Victoria Mateos,Meletios A. Dimopoulos,Michele Cavo,Kenshi Suzuki,Andrzej Jakubowiak,Stefan Knop,Chantal Doyen,Paulo Sérgio Lucio,Zsolt Nagy,Polina Kaplan,Ludek Pour,Mark Cook,Sebastian Grosicki,Andre Crepaldi,Anna Marina Liberati,Philip Campbell,Tatiana Shelekhova,Sung-Soo Yoon,Genadi Iosava,Tomoaki Fujisaki,Mamta Garg,Christopher Chiu,Jianping Wang,Robin Carson,Wendy Crist,William Deraedt,Huong Nguyen,Ming Qi,Jesús F. San-Miguel +28 more